S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:PYPD

PolyPid (PYPD) Stock Price, News & Analysis

$5.00
+0.30 (+6.38%)
(As of 03/28/2024 ET)
Today's Range
$5.00
$5.50
50-Day Range
$4.64
$6.99
52-Week Range
$3.57
$14.70
Volume
4,573 shs
Average Volume
7,489 shs
Market Capitalization
$24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
PYPD stock logo

About PolyPid Stock (NASDAQ:PYPD)

PolyPid Ltd., a clinical-stage pharmaceutical company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which helps in the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

PYPD Stock Price History

PYPD Stock News Headlines

A lot of people are making this costly mistake
You may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time.
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
PolyPid Ltd. (PYPD)
PolyPid's Earnings: A Preview
See More Headlines
Receive PYPD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PolyPid and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/14/2024
Today
3/29/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:PYPD
Fax
N/A
Employees
57
Year Founded
N/A

Profitability

Net Income
$-23,860,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($1.27) per share

Miscellaneous

Free Float
3,612,000
Market Cap
$24 million
Optionable
Optionable
Beta
1.43
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Ms. Dikla Czaczkes Akselbrad (Age 51)
    CEO & Director
    Comp: $422.33k
  • Ms. Dalit Hazan (Age 53)
    Executive Vice President of R&D and Clinical & Regulatory Affairs
    Comp: $312.25k
  • Mr. Ori Warshavsky (Age 46)
    Chief Operating Officer - US
    Comp: $335.52k
  • Mr. Jonny Missulawin (Age 37)
    Chief Financial Officer
  • Ms. Maria Rubin
    Vice President of Operations
  • Mr. Tal Vilnai
    General Counsel & Corporate Secretary
  • Ms. Rivi Lev-ari
    Vice President of Human Resource
  • Dr. Jean-Marc Hagai Pharm.D.
    Chief Commercial Officer

PYPD Stock Analysis - Frequently Asked Questions

Should I buy or sell PolyPid stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PolyPid in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PYPD shares.
View PYPD analyst ratings
or view top-rated stocks.

How have PYPD shares performed in 2024?

PolyPid's stock was trading at $3.80 at the beginning of the year. Since then, PYPD shares have increased by 31.6% and is now trading at $5.00.
View the best growth stocks for 2024 here
.

When is PolyPid's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our PYPD earnings forecast
.

How were PolyPid's earnings last quarter?

PolyPid Ltd. (NASDAQ:PYPD) released its earnings results on Wednesday, February, 14th. The company reported ($3.97) EPS for the quarter, missing the consensus estimate of ($2.17) by $1.80.

When did PolyPid's stock split?

PolyPid's stock reverse split before market open on Thursday, September 21st 2023. The 1-30 reverse split was announced on Wednesday, September 20th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, September 20th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of PolyPid own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PolyPid investors own include Advanced Micro Devices (AMD), Moderna (MRNA), Sorrento Therapeutics (SRNE), Trevena (TRVN), Cardinal Health (CAH), Genocea Biosciences (GNCA), LightPath Technologies (LPTH), Stride (LRN) and Livongo Health (LVGO).

When did PolyPid IPO?

PolyPid (PYPD) raised $50 million in an initial public offering on Friday, June 26th 2020. The company issued 3,100,000 shares at a price of $15.00-$17.00 per share. Barclays and BMO Capital Markets acted as the underwriters for the IPO and Raymond James, National Securities Corporation, Oddo BHF and A.G.P. were co-managers.

Who are PolyPid's major shareholders?

PolyPid's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of PolyPid?

Shares of PYPD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PYPD) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners